Related Experiment Video
Updated: Sep 12, 2025

Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Comparative Effectiveness of SGLT2 Inhibitors and Semaglutide in Diabetic Nephropathy: A Retrospective Observational
1Internal Medicine, Aster DM Healthcare, Dubai, ARE.
None:
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated renal benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM). This study compares renal outcomes and metabolic parameters in 10 patients with early diabetic nephropathy, five treated with SGLT2 inhibitors (empagliflozin or dapagliflozin) and five with semaglutide, a type of GLP-1 receptor agonist. Over a six-month follow-up, both groups showed improvement in albuminuria and estimated glomerular filtration rate (eGFR) stabilization. However, semaglutide recipients had greater reductions in body weight and HbA1c, while SGLT2 inhibitor users exhibited more consistent declines in albuminuria. Both agents were well tolerated. This comparative series highlights the complementary nephroprotective profiles of both drug classes, supporting their individualized use in managing diabetic kidney disease. Further randomized trials are warranted to determine optimal sequencing or combination strategies.
Related Concept Videos
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Sulfonylureas
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

